

IGF1 LR3 - 0.1mg

Tested for: Lexar
lab@domain.com

COA #: COA-2026-A96LO
Lot Number: IGF0002
Accession #: ACC-2026-72323
Labeled Content: 0.1mg

Analysis Date: 08/03/2026
Appearance: Good
Sample Matrix: Lyophilized
Date Received: 07/31/2026



IGF1 LR3 0.1mg - IGF0002

Method: Full QC Panel


Identity
IGF1 LR3

Peptide Purity
99.02%  Fentanyl Free

Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.02%	%	PASS
Net Peptide Content	Report Only	0.13	mg	N/A
Identity (HPLC-RTM)	IGF1 LR3	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS

HPLC Chromatogram



Representative chromatogram, Conformity V1

HPLC Conformity Testing Results (2 samples tested)

Sample	Purity	NPC	ID	Result
Dedicated V0	99.02%	0.13 mg	Confirmed	PASS
Conformity V1	99.63%	0.6 mg	Confirmed	PASS
Mean	99.22%	0.10 mg	—	—
Std Dev	0.1100%	0.0750 mg	—	—


Harmon Lee
Reviewed and approved by:

COA #: COA-2026-A96LO
Issued: 8/3/2026

Heavy Metals Analysis (ICP-MS)

Test	Specification	Result	Status
Arsenic (As)	NMT 1.5 ppm	Not Detected	PASS
Cadmium (Cd)	NMT 0.5 ppm	Not Detected	PASS
Lead (Pb)	NMT 1.0 ppm	Not Detected	PASS
Mercury (Hg)	NMT 1.5 ppm	Not Detected	PASS
Chromium (Cr)	NMT 10.0 ppm	Not Detected	PASS

Sterility Testing (PCR)

Test	Specification	Result	Status
Sterility (PCR)	No Growth	No Growth	PASS

Endotoxin Testing (USP <85>)

Test	Specification	Result	Status
Endotoxin (USP <85>)	Report Result	NMT 0.05 EU/mL	Reported
About this result: Endotoxin is reported as a quantitative value. Acceptable limits vary by product type and matrix, so no universal pass/fail threshold applies to RUO products.			

Notes & Methodology

1. Date Tested: 08/03/2026. Methods: Purity, Identity & Quantitation (HPLC).
2. The sample was confirmed to be IGF1 LR3 . Identification by chromatographic retention time comparison with a reference standard.
3. Elemental impurities analyzed by ICP-MS per USP <233> methodology. Acceptance criteria are internal laboratory quality screening limits for research-use materials and do not represent evaluation against any specific pharmacopeial monograph or product specification.
4. Endotoxin tested per USP <85> kinetic turbidimetric method. Acceptance criteria per client specification.
5. Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.



Harmon Lee

Reviewed and approved by:

COA #: COA-2026-A96LO

Issued: 8/3/2026